Regeneron’s COVID-19 Response Efforts
www.regeneron.com › covid19Dec 22, 2021 · The U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for REGEN-COV ® (casirivimab and imdevimab) for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Regeneron’s COVID-19 Response Efforts
https://www.regeneron.com/covid1922.12.2021 · Regeneron is applying our 30 years of scientific and technology expertise to combat the COVID-19 pandemic. We feel uniquely positioned to face this public health threat given our proprietary VelociSuite ® technologies and our track record against infectious diseases such as Ebola. We have moved REGEN-COV ® (casirivimab and imdevimab) from discovery to late …